Meanwhile, Relyvrio has already been conditionally approved in Canada under the Albrioza brand name, although it has not yet launched there, as Amylyx remains in pricing negotiations.

Shares in Amylyx have cratered after the company reported a confirmatory trial of its amyotrophic lateral sclerosis (ALS) therapy Relyvrio missed all its objectives, putting its accelerated ...

Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.